(S1 (S (NP (NP (DT The) (NN Effect)) (PP (IN of) (NP (NNS Corticosteroids))) (PP (IN on) (NP (NP (NN GATA-3) (JJ Nuclear) (NN Translocation)) (CC and) (NP (NN IL-4) (NN mRNA)))))))
(S1 (S (S (NP (NNS Corticosteroids)) (VP (VBP are) (ADJP (JJ effective)) (PP (IN in) (S (VP (VBG inhibiting) (NP (JJ GATA-3-regulated) (NN IL-4) (NN gene) (NN expression)) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))))) (PRN (-LRB- -LSB-) (NP (CD 32)) (-RRB- -RSB-)))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NNS corticosteroids)) (VP (VBP affect) (NP (NP (JJ anti-CD3/CD28-stimulated) (JJ nuclear) (NN import)) (PP (IN of) (NP (NN GATA-3))))))))) (. .)))
(S1 (S (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (NNS cells))) (PP (IN with) (NP (NN anti-CD3/CD28)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ rapid) (JJ cytoplasmic/nuclear) (NN GATA-3) (NN translocation)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1A)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG confirming) (NP (PRP$ our) (JJ previous) (NNS results)))) (PRN (-LRB- -LSB-) (NP (CD 12)) (-RRB- -RSB-)))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD confirmed) (NP (NP (DT a) (JJ clear) (NN separation)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ nuclear)) (CC and) (ADJP (JJ cytosolic))) (NNS fractions) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NN histone) (NN H1))))))) (CC and) (NP (NP (NN MEK-1) (NNS markers)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1B)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ potent) (JJ topical) (NN corticosteroid) (NN FP)) (VP (VBD caused) (NP (NP (NP (JJ sustained) (NN loss)) (PP (IN of) (NP (JJ nuclear) (NN GATA-3) (NN expression)))) (CC and) (NP (NP (JJ cytoplasmic) (NN retention)) (PP (IN of) (NP (NN GATA-3))))) (PP (IN at) (NP (NP (NNS concentrations)) (VP (VBG ranging) (PP (IN from) (NP (NP (QP (CD 10-12) (TO to) (CD 10-8)) (NN M)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP cover) (NP (NP (DT the) (JJ therapeutic) (NN range)) (-LRB- -LSB-) (CD 37) (-RRB- -RSB-)))))))))))) (. .)))
(S1 (S (NP (DT This) (NN effect)) (VP (VP (VBD was) (ADJP (ADJP (NN concentration-)) (CC and) (ADJP (JJ time-dependent))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ peak) (NN effect)) (PP (IN of) (NP (NN 11.6-fold))) (PP (IN at) (NP (NP (CD 30) (NN min)) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (NP (NN 10-8) (NN M)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1C)) (-RRB- -RRB-))))))))))) (CC and) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ marked) (NNS reductions)) (PP (IN in) (NP (NP (NP (JJ anti-CD3/CD28-stimulated) (NN IL-4) (CC and) (NN IL-5) (NN mRNA) (NN expression)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1D)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (NN loss)) (PP (IN of) (NP (NP (NN GATA-3)) (VP (VBG binding) (PP (TO to) (NP (DT the) (NP (NP (JJ native) (NN IL-5) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1E)) (-RRB- -RRB-)))))))))))))))) (. .)))
